Servier presents four-year results from Phase 2 FIREFLY-1 study of OJEMDA in pediatric low-grade glioma at SNO 2026
Servier presents four-year FIREFLY-1 data: OJEMDA shows 50.9-month median time to next treatment in pediatric low-grade glioma.
ALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Servier presents four-year FIREFLY-1 data: OJEMDA shows 50.9-month median time to next treatment in pediatric low-grade glioma.
Read MoreUS loses measles elimination status after 26 years; PAHO cites 12-month transmission and 5,400+ cases in 2026.
Read MoreCDC reports 5,182 measles cases in US, highest since 1991, with 8 deaths; 96% of cases among unvaccinated or unknown status.
Read MoreLp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.
Read MoreU.S. infant bleeding episodes rise as vitamin K shot refusals grow; rate fell from 97.7% to 95% (2017-2025) amid declining trust.
Read MoreFDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.
Read MoreFDA grants accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma.
Read MoreThe FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.
Read MoreThe U.S. HHS awarded $247.9 million in grants to expand mental health and addiction treatment services nationwide.
Read MoreA Doctors Without Borders worker infected with Bundibugyo virus during DRC Ebola outbreak was evacuated to the Netherlands for specialized treatment.
Read More